Atossa Therapeutics, Inc.

NasdaqCM:ATOS 株式レポート

時価総額：US$150.9m

このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Atossa Therapeutics マネジメント

マネジメント 基準チェック /34

Atossa Therapeutics'の CEO はSteve Quayで、 Apr2009年に任命され、 の在任期間は 15.17年です。 の年間総報酬は$ 2.36Mで、 30%給与と70%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.002%を直接所有しており、その価値は$ 3.18K 。経営陣と取締役会の平均在任期間はそれぞれ3.4年と12.3年です。

主要情報

Steve Quay

最高経営責任者

US$2.4m

報酬総額

CEO給与比率30.0%
CEO在任期間15.2yrs
CEOの所有権0.002%
経営陣の平均在職期間3.4yrs
取締役会の平均在任期間12.3yrs

経営陣の近況

Recent updates

Atossa Therapeutics (NASDAQ:ATOS) Is In A Good Position To Deliver On Growth Plans

Mar 07
Atossa Therapeutics (NASDAQ:ATOS) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Nov 08
We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth

Apr 26
Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth

We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Jan 09
We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Atossa Therapeutics: Still Gets An 'Incomplete' Rating

Oct 11

We're Hopeful That Atossa Therapeutics (NASDAQ:ATOS) Will Use Its Cash Wisely

Sep 25
We're Hopeful That Atossa Therapeutics (NASDAQ:ATOS) Will Use Its Cash Wisely

Atossa Therapeutics GAAP EPS of -$0.05

Aug 08

Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth

May 12
Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth

A First Assessment On Atossa Therapeutics

Dec 10

We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Dec 02
We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Atossa Therapeutics: Diversification Into COVID Makes Sense In A Variants World

Sep 22

Atossa Therapeutics (NASDAQ:ATOS) Is In A Strong Position To Grow Its Business

Jul 17
Atossa Therapeutics (NASDAQ:ATOS) Is In A Strong Position To Grow Its Business

Atossa Therapeutics: Hope Springs Eternal

Jun 30

Atossa Therapeutics to be included in the Russell 2000, 3000 indexes

Jun 16

Atossa reaches a two-year high ahead of data readout for breast cancer therapy

Jun 07

Atossa Therapeutics (NASDAQ:ATOS) Is In A Good Position To Deliver On Growth Plans

Apr 02
Atossa Therapeutics (NASDAQ:ATOS) Is In A Good Position To Deliver On Growth Plans

Atossa updates on single-patient study for Endoxifen

Feb 04

Atossa halts Endoxifen breast cancer study after positive data

Feb 02

Atossa Therapeutics prices ~$25M direct offering, stock -23% PM

Jan 06

Atossa Therapeutics prices $14M registered direct offering

Dec 17

We're A Little Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Dec 10
We're A Little Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Atossa Therapeutics plummets 38% after it raises $20M in public offering

Dec 09

Atossa Therapeutics EPS in-line

Nov 13

Safety data on COVID-19 nasal spray fails to lift Atossa, down 6%

Nov 10

CEO報酬分析

Atossa Therapeutics の収益と比較して、Steve Quay の報酬はどのように変化したか？
日付総報酬給与会社業績
Mar 31 2024n/an/a

-US$30m

Dec 31 2023US$2mUS$706k

-US$30m

Sep 30 2023n/an/a

-US$30m

Jun 30 2023n/an/a

-US$32m

Mar 31 2023n/an/a

-US$28m

Dec 31 2022US$3mUS$706k

-US$27m

Sep 30 2022n/an/a

-US$24m

Jun 30 2022n/an/a

-US$21m

Mar 31 2022n/an/a

-US$22m

Dec 31 2021US$6mUS$659k

-US$21m

Sep 30 2021n/an/a

-US$28m

Jun 30 2021n/an/a

-US$26m

Mar 31 2021n/an/a

-US$23m

Dec 31 2020US$3mUS$601k

-US$22m

Sep 30 2020n/an/a

-US$13m

Jun 30 2020n/an/a

-US$13m

Mar 31 2020n/an/a

-US$16m

Dec 31 2019US$6mUS$601k

-US$17m

Sep 30 2019n/an/a

-US$17m

Jun 30 2019n/an/a

-US$17m

Mar 31 2019n/an/a

-US$25m

Dec 31 2018US$2mUS$582k

-US$23m

Sep 30 2018n/an/a

-US$23m

Jun 30 2018n/an/a

-US$22m

Mar 31 2018n/an/a

-US$11m

Dec 31 2017US$1mUS$520k

-US$11m

報酬と市場: Steveの 総報酬 ($USD 2.36M ) は、 US市場 ($USD 1.58M ) の同規模の企業の平均を上回っています。

報酬と収益: Steveの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Steve Quay (73 yo)

15.2yrs

在職期間

US$2,356,220

報酬

Dr. Steven C. Quay, also known as Steve, M.D., Ph D., FCAP, has been the Chief Executive Officer and President of Atossa Therapeutics, Inc. (formerly known as Atossa Genetics Inc.) since April 30, 2009 and...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Steven Quay
Chairman15.2yrsUS$2.36m0.0021%
$ 3.2k
Heather Rees
Senior VP of Finance & Principal Accounting Officer3.4yrsUS$687.46k0%
$ 0
Delly Behen
Senior Vice President of Administration & HR9.9yrsデータなしデータなし
Eric Van Zanten
Vice President of Investor & Public Relations2.4yrsデータなしデータなし
Richard Graydon
Interim Chief Medical Officer1.7yrsデータなしデータなし

3.4yrs

平均在職期間

経験豊富な経営陣: ATOSの経営陣は 経験豊富 であると考えられます ( 3.4年の平均在職年数)。

取締役

名称ポジション在職期間報酬所有権
Steven Quay
Chairman15.2yrsUS$2.36m0.0021%
$ 3.2k
Richard Steinhart
Independent Director10.3yrsUS$146.17k0%
$ 0
H. Remmel
Independent Director12.3yrsUS$144.92k0.00020%
$ 301.8
Shu-Chih Chen
Director15.2yrsUS$116.17k0.018%
$ 26.7k
Stephen Galli
Independent Director12.9yrsUS$144.92k0.000080%
$ 120.7
Jonathan Finn
Independent Directorless than a yearUS$93.98k0.020%
$ 30.0k
Tessa Cigler
Independent Directorless than a yearデータなしデータなし

12.3yrs

平均在職期間

67yo

平均年齢

経験豊富なボード: ATOSの 取締役会 は経験豊富で 経験豊富 です ( 12.3年の平均在任期間)。